{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-020697","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2023-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.901342+00:00","generated_at":"2026-06-14T07:57:58.045029+00:00","sec_items":["4.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cumberland Pharmaceuticals appoints Carr, Riggs & Ingram as new independent auditor for FY 2023","bullets":["Appointed CRI as independent registered public accounting firm for FY ending Dec 31, 2023, effective for interim period ending June 30, 2023.","No prior consultations with CRI on accounting principles or audit opinion type.","No disagreements or reportable events between the company and predecessor auditor as defined in Regulation S-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-020697","json":"https://secwatch.observer/filing/0001628280-23-020697.json","markdown":"https://secwatch.observer/filing/0001628280-23-020697.md","text":"https://secwatch.observer/filing/0001628280-23-020697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023020697/0001628280-23-020697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023020697/cpix-20230530.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:57:58.045029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}